Stephanie L. Graff, MD FACP FASCO

Brown Paper Bags

“In giving, we are connected. Gifts speak for us when the weight of emotion and the vulnerability of truth are too much.”

Brown Paper Bags | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

Invisible in the Metrics of Academic Oncology | JCO Oncology Practice

“Who decides who decides?”

Partnered w/ @shrutipatelmd.bsky.social on this editorial from Dr. Campbell & @laurabukavinamd.bsky.social work in which we explore how altmetrics & digital clout are shaped by systemic bias

#MedSky #WomenInMedicine
ascopubs.org/doi/10.1200/...

⛱️☀️📖 You have heard of “light summer beach reads” — and now @JCO_ASCO brings you “stirring, emotionally powerful, reflective narrative summer writing” (practically the same, right??)

But really, what a wonderful opportunity for young writers. ✍🏻📝👨‍💻 @oncoalert.bsky.social

ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cr up oss over design. #ASCO25 @oncoalert.bsky.social

VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25

Reflex cDNA-methylation multi-cancer early detection (MCED) test achieved meaningful per-cancer intrinsic accuracy & per-tissue of origin PPV across mult cancer types evaluated in at-risk indiv w/obesity. #ASCO25 @oncoalert.bsky.social

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged.

27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25

@oncoalert.bsky.social

AI-assisted training changed HER-2 low, ultra low, null classification in this analysis by Marina DeBrot et al #ASCO25

Kicking off breast sessions #ASCO25 with the data that Black patients with breast cancer continue to have worse overall survival in the modern-HER2 era. Adjusted HR 1.28 @oncoalert.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@elisaagostinetto.bsky.social‬
@erikahamilton9.bsky.social‬
@drsgraff.bsky.social‬
@elisabettabonzano.bsky.social‬

Join me & Maryam Lustberg at #ASCO25 at #OncForum2025 to discuss ADCs, sequencing, HER2 low/ultra-low, biomarkers, and “right-sizing” early stage disease

Saturday June 1 at 7:15- 7:45 PM
Duneyrr Fermenta & Brewery
2337 S. Michigan Ave.

Register now! app.smartsheet.com/b/form/7e557...

Honored and humbled to be awarded the 2025 E. Grey Diamond Take Wing Award, my school’s highest alumni honor. Thank you, Dean Norbash, my amazing family, members of the awards committee— I am proud to embody the spirit of UMKC SOM in all that I do.

In <1 minute, use @ascocancer.bsky.social link to #ProtectMedicaid. Maybe you think it isn’t about you—but sometimes patients w/cancer lose their job, insurance is tied to employment, then suddenly—Medicaid is about them. Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd

Congress is considering cuts to Medicaid during its budget reconciliation process. 70 million ppl receive health coverage under Medicaid, including those w/ cancer. We must #ProtectMedicaid! #ASCOAdvocacy

Urge members of congress to safeguard Medicaid➡️ brnw.ch/21wSxGD

Oncologists—
The @ascocancer.bsky.social #ASCO24 #IDEA awardees are conducting a study to understand and identify barriers, opportunities, and strategies to improve evidence-based cancer care globally. Take a quick survey here:
forms.office.com/pages/respon...
Cc. @oncoalert.bsky.social

Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...

In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42

Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social

ascopubs.org/doi/10.1200/...

The Essential Connection Between Healthy Lifestyle & Cancer ... : Oncology Times An abstract is unavailable.

Check out this cool profile on all things @dramycomander.bsky.social and Lifestyle Oncology!! @oncologytimes.bsky.social

journals.lww.com/oncology-tim...

REAL ID will be *really real* by #ASCO25 —make sure your ID is airport ready. ✈️
@ascocancer.bsky.social @oncbrothers.bsky.social @oncoalert.bsky.social @narjustflorezmd.bsky.social @drchoueiri.bsky.social @erikahamilton9.bsky.social @drdonsdizon.bsky.social @drteplinsky.bsky.social

The act will disenfranchise vets/active/overseas military from voting as well (who often have less access to reams of documents)

LDF Denounces House Passage of SAVE Act, Urges Senate to Reject Bill that Will Disenfranchise Millions of Americans - naacpldf.org/press-release/…

#HellNo #VotesForVets

Married women who have their husbands last name may need to show 3+ legal documents to verify voter eligibility

LDF Denounces House Passage of SAVE Act, Urges Senate to Reject Bill that Will Disenfranchise Millions of Americans -

#HellNo #VotesForWomen

www.naacpldf.org/press-releas...

This ⬇️

Justice Sotomayor with a bone-chilling dissent today: “The implication of the govt’s position is noncitizens AND US citizens could be taken off streets, forced onto planes, confined to foreign prisons with no opportunity for redress…This Nation's laws is designed to prevent, not en-able, their rise.

SWOG leaders at ASCO Advocacy Summit 2025

@swog.org leaders at @ascocancer.bsky.social #ASCOAdvocacySummit 2025 in DC:
Drs. Paul Hesketh, Charles Blanke, Anne Chiang, Raymond Osarogiagbon, Rafeh Naqash.
Goals:
- Robust federal funding for #CancerResearch, NCI, & NIH
- #FixPriorAuth
- #DrugShortages solutions

An honor to meet w/Rep.Magaziner staff, Raisa Majid with Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug
Shortages. @ascocancer.bsky.social

Engage in ASCO's Advocacy Efforts Write a letter to your lawmaker today!

Want to join us in our efforts? Visit asco.org/actnetwork to contact your Members of Congress about the issues that matter most to you! Advocates are also on the Hill to fix #PriorAuth and protect #CancerResearch funding. #ASCOAdvocacy @ascocancer.bsky.social

I am urging lawmakers to ensure long-term stability for oncology treatments, which will ultimately save and prolong lives. With transparency and strong manufacturing, this is preventable. #ASCOAdvocacySummit #drugshortages @ascocancer.bsky.social

We ask Congress & the Administration to intervene to secure the pharmaceutical pipeline & address #drugshortages

I have written guidance position⬇️ sat w/clinic pts deciding what to do when we run out of their cancer drug #ASCOAdvocacySummit @ascocancer.bsky.social

🔗 www.asco.org/practice-pat...